| Mr Robert Russell Taverner, LCMFT | |
|
787 Avenue N, Chase, KS 67524-9462 | |
| (620) 938-9949 | |
| Not Available |
| Full Name | Mr Robert Russell Taverner |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 787 Avenue N, Chase, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275702615 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 134 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Robert Russell Taverner, LCMFT 787 Avenue N, Chase, KS 67524-9462 Ph: (620) 938-9949 | Mr Robert Russell Taverner, LCMFT 787 Avenue N, Chase, KS 67524-9462 Ph: (620) 938-9949 |
News Archive
A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.
Eighty percent of American voters favor national standards that would limit calories, fat, and sodium in snack and - la carte foods sold in U.S. schools and encourage the consumption of fruits, vegetables and low-fat dairy items, according to a new poll commissioned by the Kids' Safe & Healthful Foods Project, a joint project of The Pew Charitable Trusts and the Robert Wood Johnson Foundation.
Following more than two years of unsuccessful attempts to convince the management of Cassellholme Home for the Aged in North Bay to fulfill its obligation to rectify staff and supply shortages, the Ontario Nurses' Association (ONA) has taken the rare step of calling for an Independent Assessment Committee hearing into RN staffing levels at the facility.
Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.
› Verified 3 days ago